Adrenergic Agonists Flashcards
Epinephrine receptors
A1, a2, b1, b2
Norepinephrine receptors
A1, a2, b1
Isoproterenol receptors
B1, b2
Dopamine receptors
D1 > B2 > a1
Dobutamine receptors
B1
Phenylephrine receptors
A1
Clonidine recpetors
A2
Terbutaline receptors
B2
Mirabegron receptors
B3
Ephedrine recpeotrs
Non selective a/b; mixed acting
Norepinephrine use
Severe hypotensive states
Preferred vasopressor for septic shock
Epinephrine use
Prolong local anesthetics (a1) Anaphylactic shock (a1, B1, B2) Ashtma (B2) Topical hemostasis (a1) Cardiac arrest (B1)
Isoproterenol use
AV block
Cardiac arrest
Bronchospasm during anesthesia
Dopamine use
Shock (esp accompanied by low CO & compromised renal fcn)
Maintain systemic BP in hypotensive patients w/ sepsis
Dobutamine use
Cardiac stimulant for short term treatment of severe refractory CHF
Phenylephrine use
Nasal decongestant
Vasopressor
Mydriatic
Detumescent
Clonidine use
HTN
ADHD
Severe pain (epidural)
Many off label uses
Terbutaline use
Decrease airway resistance in asthmatics & COPD
Off label: tocolytic: suppress premature labor
Mirabegron use
Overactive bladder
Ephedrine use
Anesthesia induced hypotension
Methylphenidate use
ADHD: immediate onset
Narcolepsy
Atomeoxetine use
ADHD: re-uptake inhibition immediate, efficacy delayed (1-3 weeks)
Less abuse potential, not controlled
SE epinephrine
Hypertensive crisis (a1) Dysrhythmias (B1) Angina (a1, B1) Extravasation induced necrosis (a1) Hyperglycemia (B2)
DI of epinephrine
MAOI (pheneizine)
TCA (imipramine)
General anesthetics (halothane)
A & B blockers (prazosin, propranolol)
SE of dobutamine
Tachycardia/arrhythmias
THN
Intensified by MAOIs (90% dose decrease in these patients)
CI in dobutamine
Ischemic heart disease
Phenylephrine toxicity
Reflex bradycardia (decrease CO), excitability, restlessness, HTN
Overdose: vomiting, HTN, palpitations, arrhythmias
SE clonidine
Bradycardia
Dry mouth
Sedation
Rebound HTN upon abrupt withdrawal
Terbutaline SI
Tremor, hyperglycemia
Tachycardia at increased dose
BBW for terbutaline
Adverse CV events & death in pregnant women
CI mirabegron
GI (Nausea, diarrhea, const)
Tachycardia
Urinary retention
Increase BP
CI of mirabegron
Inhibits CYP2D6
M antagonists
Ephedrine SE
HTN
Insomnia
Methylphenidate SE
CV events, peripehral vasculopathy & priapism (rare)
Insomnia
Appetite decrease
Tics
Tolerance, physical dependence & withdrawal
BBW methylphenidate
Abuse potential
SE atomeoxetine
Dizziness
Insomnia
Decrease dappetite
Priapism
Orthostatic tachycardia
Increase BP
Suicidal thoughts children/adolescents
Catecholamines
Not orally effective
Short DOA
Do not cross BBB
Non-catecholamines
No catechol group
Orally effective
Long DOA CNS effects